Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz. The 4,500 m2 centre houses chemical and analytical facilities, laboratories and advanced technologies including flow chemistry, distillation and process analytics, plus office space. There are workspaces for over 100 and 40 new jobs have been created.
Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland. The company is investing up to €23 million at the facility, which will begin operations in 2024 and host about 100 scientists, working alongside another R&D centre at the main site in Zofingen. The centre will host advanced chemical and analytical facilities and laboratories, offering chemical process R&D and analytical development services for the entire drug substances network, Siegfried said.
